In testimony presented to a U.S. House of Representatives Judiciary subcommittee the Federal Trade Commission described its ongoing efforts to protect competition and consumers in many important sectors of the economy, including health care, pharmaceuticals, and technology.
The Federal Trade Commission held a workshop to explore competition issues involving biologic medicines and follow-on biologics. As described in the Federal Register Notice, the workshop focused on a few key issues, inter alia:
Series of hearings:
December 5, 2008
February 11-12, 2009
March 18-19, 2009
April 17, 2009
May 4-5, 2009
The FTC challenged Ardagh Group, S.A.’s proposed $1.7 billion acquisition of Saint-Gobain Containers, Inc., alleging that it will reduce competition and result in the two firms – the merged firm and its only remaining significant competitor, Owens-Illinois – controlling in excess of...
The Federal Trade Commission will host a one-day public workshop on December 10, 2013, at its headquarters in Washington, DC, to examine competition issues surrounding biologic and follow-on biologic medications.
To find more on these FTC cases, use the improved Search function with new drop-down menus and keyword searching.
The FTC will hold hearings this fall to address whether there have been broad-based changes in the contemporary competitive environment that require any adjustments in antitrust and consumer protection enforcement in order to keep pace with those changes.
A series of FTC and DOJ hearings.
The Federal Trade Commission and Department of Justice will commence public hearings in Washington, D.C. on February 26, 2003 on the implications of competition law and policy for health care financing and delivery. The hearings will broadly consider the impact of competition law and...
FTC and DOJ hearings. The Antitrust Division and the Federal Trade Commission (FTC) cohosted hearings on single-firm conduct and antitrust law in 2006 and 2007. To see the Presentations, please visit DOJ's website: http://www.justice.gov/atr/public/hearings/single_firm/sfcjune.html...
The Federal Trade Commission issued final changes to the premerger notification rules that require companies in the pharmaceutical industry to report certain proposed acquisitions of exclusive patent rights to the FTC and the Department of Justice for antitrust review.
The Federal Trade Commission has unanimously voted to close its seven-month investigation into the proposed $1.2 billion merger of office supply superstores Office Depot, Inc. and OfficeMax, Inc. and has issued a Commission statement detailing the basis for its decision.
The Federal Trade Commission has approved a request by Kinder Morgan, Inc., that the Commission modify the final FTC order and approve a change to a related divestiture agreement. The order resolved Commission charges that Kinder Morgan’s 2012 acquisition of El Paso Corporation would harm...
Under a settlement with th FTC, Mylan, Inc., and Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila) divested 11 generic injectable drugs as a condition of allowing Mylan’s proposed acquisition of Agila from Strides Arcolab Ltd. (Strides)....
In light of the recent, temporary government shutdown, the Federal Trade Commission is extending the public comment periods for 13 matters that currently are pending before the agency in order to ensure that interested parties have a full opportunity to file comments. The Commission also...
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Solera Holdings, Inc.’s 2012 purchase of rival Actual Systems of America, Inc. was anticompetitive. The FTC's complaint alleges that the acquisition significantly harmed competition in...
Under a settlement, the FTC required Watson Pharmaceuticals, Inc. and Actavis Inc.
Following an appeal by RealComp, the United States Court of Appeals for the Sixth Circuit upheld the FTC order. On August 15, 2011 Realcomp appealed to the Supreme Court. On October 11, 2011 the Supreme Court denied Realcomp's petition for a writ of certiorari.
There is a related administrative proceeding.